PharmaCyte Biotech (PMCB) Return on Capital Employed (2011 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Return on Capital Employed of 13.58% for Q2 2026, down 418.0% year-over-year from 4.27% in Q2 2025, and down 36.77% quarter-over-quarter from 9.93% in Q1 2026.
PharmaCyte Biotech (PMCB) Return on Capital Employed (2011 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Return on Capital Employed for 16 consecutive years, with 13.58% the latest figure, recorded in Q2 2026.
- In Q2 2026, Return on Capital Employed fell 418.0% year-over-year to 13.58%; the TTM figure through Apr 2026 stood at 13.58% (down 418.0% YoY), while the FY2026 annual figure was 13.67%, down 566.0% from the prior year.
- Return on Capital Employed retreated to 13.58% in Q2 2026 per PMCB's latest filing, from 9.93% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 4.28% in Q1 2022 and bottomed at 14.64% in Q2 2024.
- Historically, Return on Capital Employed has averaged 9.46% across 5 years, with a median of 9.01% in 2023.
- Annual changes were most pronounced in 2022 — Return on Capital Employed jumped 5601 bps — and 2024, when it tumbled 603 bps.
- PharmaCyte Biotech's Return on Capital Employed stood at 7.62% in 2022, then decreased by 5 bps to 8.01% in 2023, then slumped by 60 bps to 12.8% in 2024, then surged by 33 bps to 8.63% in 2025, then sank by 57 bps to 13.58% in 2026.
- Business Quant data shows PMCB's Return on Capital Employed at 13.58% in Q2 2026, 9.93% in Q1 2026, and 8.63% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | PharmaCyte Biotech | 4.30 Mn | 4.30 Mn | - | -13.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -13.58% |
| Jan 31, 2026 | -9.93% |
| Oct 31, 2025 | -8.63% |
| Jul 31, 2025 | -8.06% |
| Apr 30, 2025 | -9.40% |
| Jan 31, 2025 | -13.47% |
| Oct 31, 2024 | -12.80% |
| Jul 31, 2024 | -13.40% |
| Apr 30, 2024 | -14.64% |
| Jan 31, 2024 | -9.26% |
| Oct 31, 2023 | -8.01% |
| Jul 31, 2023 | -9.13% |
| Apr 30, 2023 | -8.60% |
| Jan 31, 2023 | -8.90% |
| Oct 31, 2022 | -7.62% |
| Jul 31, 2022 | -5.74% |
| Apr 30, 2022 | -4.85% |
| Jan 31, 2022 | -4.28% |
| Oct 31, 2021 | -7.75% |
| Jul 31, 2021 | -61.76% |